Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Basilea Launches Complementary Phase III Trial For Anti-infective Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

New trial adds to data on isavuconazole for invasive yeast and mold infections.

You may also be interested in...



FDA Wants More Ceftobiprole Data From J&J/Basilea

Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.

Start-Up Spotlight: Procyrion Trials Novel Device To Tackle Cardiorenal Syndrome

To help patients suffering from cardiorenal syndrome, an undertreated illness, Procyrion has embarked on the first in-human trials of its Aortix mechanical circulatory support device.

Start Designing Vaccines For The Next Pandemic, Urges NIH Chief

NIH director Francis Collins and former FDA commissioner Margaret Hamburg outline learnings from the COVID-19 pandemic and what needs to be done next amid concerns around the dangerous Delta and also Lambda variants. They also discuss the role of the WHO, which has “many masters to try and satisfy.”

Topics

UsernamePublicRestriction

Register

PS067573

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel